Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David R. Lieberman is active.

Publication


Featured researches published by David R. Lieberman.


Tetrahedron Letters | 1994

Synthesis of the 5-HT1D receptor agonist MK-0462 via a Pd-catalyzed coupling reaction

Cheng-yi Chen; David R. Lieberman; Robert D. Larsen; Robert A. Reamer; Thomas R. Verhoeven; Paul J. Reider; Ian F. Cottrell; Peter G. Houghton

Abstract Application of a palladium-catalyzed coupling between 3 and 5a to the synthesis of the novel 5-HT 1D receptor agonist MK-0462 ( 1 ), a potential anti-migraine drug, is described.


Journal of the American Chemical Society | 2015

Catalytic, Asymmetric, and Stereodivergent Synthesis of Non-Symmetric β,β-Diaryl-α-Amino Acids

Carmela Molinaro; Jeremy P. Scott; Michael Shevlin; Christopher Wise; Alain Ménard; Andrew D. Gibb; Ellyn M. Junker; David R. Lieberman

We report a concise, enantio- and diastereoselective route to novel nonsymmetrically substituted N-protected β,β-diaryl-α-amino acids and esters, through the asymmetric hydrogenation of tetrasubstituted olefins, some of the most challenging examples in the field. Stereoselective generation of an E- or Z-enol tosylate, when combined with stereoretentive Suzuki-Miyaura cross-coupling and enantioselective hydrogenation catalyzed by (NBD)2RhBF4 and a Josiphos ligand, allows for full control over the two vicinal stereogenic centers. High yields and excellent enantioselectivities (up to 99% ee) were obtained for a variety of N-acetyl, N-methoxycarbonyl, and N-Boc β,β-diaryldehydroamino acids, containing a diverse and previously unreported series of heterocyclic and aryl substituted groups (24 examples) and allowing access to all four stereoisomers of these valuable building blocks.


Journal of Organic Chemistry | 2011

Synthesis of Vaniprevir (MK-7009): Lactamization To Prepare a 22-Membered Macrocycle

Zhiguo J. Song; David M. Tellers; Michel Journet; Jeffrey T. Kuethe; David R. Lieberman; Guy R. Humphrey; Fei Zhang; Zhihui Peng; Marjorie S. Waters; Daniel Zewge; Andrew Nolting; Dalian Zhao; Robert A. Reamer; Peter G. Dormer; Kevin M. Belyk; Ian W. Davies; Paul N. Devine; David M. Tschaen

Development of a practical synthesis of MK-7009, a 20-membered [corrected] macrocycle, is described. A variety of ring-closing strategies were evaluated, including ring-closing metathesis, intermolecular palladium-catalyzed cross-couplings, and macrolactamization. Ring closure via macrolactamization was found to give the highest yields under relatively high reaction concentrations. Optimization of the ring formation step and the synthesis of key intermediates en route to MK-7009 are reported.


Journal of Pharmaceutical and Biomedical Analysis | 2002

Employment of on-line FT-IR spectroscopy to monitor the deprotection of a 9-fluorenylmethyl protected carboxylic acid peptide conjugate of doxorubicin

Mark Cameron; George X. Zhou; Micheal B Hicks; Vincent Antonucci; Zhihong Ge; David R. Lieberman; Joesph E Lynch; Yao-Jun Shi

A method for accurately determining the end-point, >98% conversion, of the deprotection reaction of a highly toxic 9-fluorenylmethyl (Fm) ester 1b to its corresponding carboxylate 1d in real time by FT-IR spectroscopy is reported. Advantages of this method over analysis by conventional chromatographic means include real time determination of the end-point of a reaction that is time sensitive to by-product formation, and elimination of sampling a highly toxic reaction mixture. The FT-IR method is based on monitoring, in real time, the disappearance of the Fm ester carbonyl band for 1b at 1737 cm(-1), during deprotection by piperidine, and calibration models were established by Partial Least Squares (PLS) regression analysis with high performance liquid chromatography (HPLC) as reference. The best calibration model was built with 5 PLS factors in the spectral range of 1780-1730 and 1551-1441 cm(-1) and resulted in a standard error of cross validation (SECV) of 0.63 mM 1b and a standard error of prediction (SEP) of 0.51 mM 1b in the range of 0-25 mM. This error of prediction is approximately 0.8% of the initial concentration of 1b and is well within our specifications of <2% initial concentration.


Synthetic Communications | 1996

An Efficient Synthesis of the Indole Acetic Acid Metabolite of MK-0462

Cheng-yi Chen; David R. Lieberman; Leslie J. Street; Alex R. Guiblin; Robert D. Larsen; Thomas R. Verhoeven

Abstract A palladium-catalyzed coupling of iodoaniline 2 with bis-TES propargyl alcohol 3 gives indole-3-methanol 4b in 72% yield. Displacement of the hydroxy group of 4b by sodium cyanide followed by hydrolysis of the cyano group and desilylation provides the indole acetic acid metabolite, L-749,335 (1), of the 5-HT1D receptor agonist MK-0462.


Journal of Organic Chemistry | 1994

Efficient Synthesis of Losartan, A Nonpeptide Angiotensin II Receptor Antagonist

Robert D. Larsen; Anthony O. King; Cheng Y. Chen; Edward G. Corley; Bruce S. Foster; F. Edward Roberts; Chunhua Yang; David R. Lieberman; Robert A. Reamer; David M. Tschaen; Thomas R. Verhoeven; Paul J. Reider; Young Sek Lo; Lucius Thomas Rossano; A. Sidney Brookes; David Meloni; James R. Moore; John F. Arnett


Journal of Organic Chemistry | 1997

Syntheses of Indoles via a Palladium-Catalyzed Annulation between Iodoanilines and Ketones.

Cheng-yi Chen; David R. Lieberman; Robert D. Larsen; Thomas R. Verhoeven; Paul J. Reider


Journal of Organic Chemistry | 2000

A practical and efficient preparation of the releasable naphthosultam side chain of a novel anti-MRSA carbapenem.

Ross A. Miller; Guy R. Humphrey; David R. Lieberman; Scott S. Ceglia; Derek J. Kennedy; Edward J. J. Grabowski; Paul J. Reider


Journal of Organic Chemistry | 2005

Practical Asymmetric Synthesis of a Non-Peptidic αvβ3 Antagonist

Stephen P. Keen; Cameron J. Cowden; Brian Bishop; Karel M. J. Brands; Antony J. Davies; Ulf H. Dolling; David R. Lieberman; Gavin W. Stewart


Organic Process Research & Development | 2015

Evolution of a Manufacturing Route to Omarigliptin, A Long-Acting DPP‑4 Inhibitor for the Treatment of Type 2 Diabetes

John Chung; Jeremy P. Scott; Camille Anderson; Brian Bishop; Nadine Bremeyer; Yang Cao; Qinghao Chen; Robert F. Dunn; Amude Kassim; David R. Lieberman; Aaron Moment; Faye J. Sheen; Michael J. Zacuto

Collaboration


Dive into the David R. Lieberman's collaboration.

Researchain Logo
Decentralizing Knowledge